medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2006, Número 4

<< Anterior Siguiente >>

Rev Biomed 2006; 17 (4)


Staphylococcus aureus: la reemergencia de un patógeno en la comunidad

Bustos-Martínez JA, Hamdan-Partida A, Gutiérrez-Cárdenas M

Idioma: Español
Referencias bibliográficas: 74
Paginas: 287-305
Archivo PDF: 144.02 Kb.


RESUMEN

Staphylococcus aureus es un microorganismo que posee características particulares de virulencia y resistencia a los antibióticos. En los humanos causa una amplia variedad de enfermedades infecciosas. El principal impacto de este microorganismo se debe a las cepas de S. aureus resistentes a la meticilina (MRSA), que tradicionalmente se encontraban limitadas al ámbito hospitalario, produciendo infecciones nosocomiales a nivel mundial. Sin embargo, en años recientes las cepas MRSA han aparecido en la comunidad, provocando problemas en muchos países. La prevalencia de estas cepas en la comunidad se ha incrementado sustancialmente. Si no se toman las medidas adecuadas para entender y controlar la cambiante epidemiología y sintomatología clínica, puede convertirse en un importante problema de salud en un futuro cercano. En la presente revisión se abordan las principales características de virulencia y resistencia a los antibióticos de S. aureus, los cambios recientes en la epidemiología de este microorganismo, así como las características más importantes de las cepas de S. aureus resistentes a meticilina adquiridas en la comunidad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1.- Howe RA, Brown NM, Spencer RC. The new threats of Gram positive pathogens: re-emergence of things past. J Clin Pathol 1996; 49:444-9.

  2. 2.- Velázquez-Meza ME. Surgimiento y diseminación de Staphylococcus aureus meticilinoresistente. Salud Pública Méx 2005; 47:381-7.

  3. 3.- Kanafani ZA, Fowler VG. Staphylococcus aureus infections: new challenges from an old pathogen. Enferm Infecc Microbiol Clin 2006; 24:182-93.

  4. 4.- Foster T. Staphylococcus. En: Baron S, editor. Medical Microbiology. 4a ed. [online] [Cited 2006 August 20]. Available from: URL: http://gsbs.utmb.edu/microbook

  5. 5.- Shopsin B, Kreiswirth BN. Molecular epidemiology of methicillin-resistant Staphylococcus aureus. Emerging Infect Dis 2001; 7:323-6.

  6. 6.- Chambers HF. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microb Rev 1997; 10:781-91.

  7. 7.- Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 7:178-82.

  8. 8.- Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 2000; 13:16-34.

  9. 9.- Herzer CM. Toxic shock syndrome: broadening the differential diagnosis. J Am Board Fam Pract 2001; 14:131-6.

  10. 10.- Saïd-Salim B, Mathema B, Braughton K, Davis S, Sinsimer D, Eisner W, et al. Differential distribution and expression of Panton-Valentine leucocidin among community-acquired methicillin-resistant Staphylococcus aureus strains. J Clin Microbiol 2005; 43:3373-9.

  11. 11.- Schmitt CK, Meysick KC, O’Brien AD. Bacterial toxins: friends or foes? Emerg Infect Dis 1999; 5:224-34.

  12. 12.- Moore PCL, Lindsay JA. Genetic variation among hospital isolates of methicillin-sensitive Staphylococcus aureus: evidence for horizontal transfer of virulence genes. J Clin Microbiol 2001; 39:2760-7.

  13. 13.- Foster TJ. The Staphylococcus aureus “superbug”. J Clin Invest 2004; 114:1693-6.

  14. 14.- Bronner S, Monteil H, Prévost G. Regulation of virulence determinants in Staphylococcus aureus: complexity and applications. FEMS Microbiol Rev 2004; 28:183-200.

  15. 15.- National Nosocomial Infectious Surveillance System (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85.

  16. 16.- Aires de Sousa M, Miragaia M, Santos SI, Avila S, Adamson I, Casagrande ST, et al. Three-Year assessment of methicillin-resistant Staphylococcus aureus clones in Latin America from 1996 to 1998. J Clin Microbiol 2001; 39:2197-205.

  17. 17.- Velázquez-Meza ME, Aires de Sousa M, Echaniz AG, Solórzano SF, Miranda NG, Silva SJ, de Lencastre H. Surveillance of methicillin-resistant Staphylococcus aureus in a pediatric hospital in Mexico City a 7 year period (1997 to 2003): Clonal evolution and impact of infection control. J Clin Microbiol 2004; 42: 3877-80.

  18. 18.- Alpuche-Aranda C, Avila-Figueroa C, Espinoza-De los Monteros L, Gómez-Barreto D, Santos-Preciado JI. Perfiles de sensibilidad antimicrobiana de Staphylococcus aureus en un hospital pediátrico: prevalencia de resistencia a meticilina. Bol Med Hosp Infant Mex 1989; 46:700-4.

  19. 19.- Calderón JE, Espinoza DM, Avila BR. Epidemiology of drug resistance: the case of Staphylococcus aureus and coagulase negative staphylococci infections. Salud Pública Méx 2002; 44:108-12.

  20. 20.- Macia H, Medina V, Gaona R. Estafilococos resitentes a meticilina en un hospital general de León, Guanajuato. Enfer Infect Microbiol. 1993; 3:123-7.

  21. 21.- Urdez HE, Sifuentes OJ, Calva J, Villalobos ZY. Epidemiological and biological characteristics of methicillin-resitant staphylococcal infections in Mexican Hospital. Arch Med Res 1999; 30:325-31.

  22. 22.- Saïd-Salim B, Mathema B, Kreiswirth BN. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen. Infect Control Hosp Epidemiol 2003; 24:451-5.

  23. 23.- Hiramatsu K, Cui L, Kuroda M, Ito T. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol 2001; 9:486-93.

  24. 24.- Ito T, Ma XX, Takeuchi F, Okuma K, Yuzawa H, Hiramatsu K. Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob Agents Chemoter 2004; 48:2637-51.

  25. 25.- Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, Kobayashi I, et al. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 2001; 357:1225-40.

  26. 26.- Oliveira DC, Lencastre H. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin resistant Staphylococcus aureus. Antimicrob Agents Chemoter 2002; 46:2155-61.

  27. 27.- Ma XX, Ito T, Tiensasitorn C, Jamklang M, Chongtrakool P, Boyle-Vavra S, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicro Agents Chemother 2002; 46:1147-52.

  28. 28.- Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resitance. Surgical Infect 2005; 6:283-95.

  29. 29.- Srinivasan A, Dick JD, Perl TM. Vancomycin resistance in staphylococci. Clin Microbiol 2002; 15:430-8.

  30. 30.- Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 2003; 111:1265-73.

  31. 31.- Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resitance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicro Agents Chemo 2003; 47:3040-5.

  32. 32.- Wilcox MH. Efficacy of linezolid versus comparator therapies in Gram-positive infections. J Antimicro Chemo 2003; 51 (Suppl. S2): ii27-ii35.

  33. 33.- Marcos Vivoni A, Meurer Moreira B. Application of molecular techniques in the study of Sthapylococcus aureus clonal evolution – A review. Mem Inst Oswaldo Cruz 2005; 100:693-8.

  34. 34.- Echániz Aviles G, Velázquez Meza ME, Aires de Sousa M, Morfín Otero R, Rodríguez Noriega E, Carnilla Barajas N, et al. Molecular characterisation ofa dominant methicillin-resistant Sthapylococcus aureus (MRSA) clone in a Mexican hospital (1999-2003). Clin Microbiol Infect 2006; 12:22-8.

  35. 35.- Crisóstomo MI, Westh H, Tomasz A, Chung M, Oliveira DC, de Lencastre H. The evolution of methicillin resitance in Sthapylococcus aureus: similarity of genetic backgrounds in historically early methicillin-susceptible and –resistant isolates and contemporary epidemic clones. Proc Natl Acad Sci USA 2001; 98:9865-70.

  36. 36.- Enright MC, Ashley AD, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant Sthapylococcus aureus (MRSA). Proc Natl Acad Sci USA 2002; 99:7687-92.

  37. 37.- Johnson DRP, Howden PB, Bennett CM. Sthapylococcus aureus: a guide for the perplexed. Med J Aust 2006; 184:374-5.

  38. 38.- Ponce de León S, Rangel-Frausto M, Elías-López JI, Romero-Oliveros C, Huertas-Jiménez M. Infecciones nosocomiales: tendencias seculares de un programa de control en México. Salud Pública Méx 1999; 41 (Suppl 1):S5-S11.

  39. 39.- Tapia CR. Infecciones nosocomiales. Salud Pública Méx 1999; 41 (Suppl 1):S3-S4.

  40. 40.- Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999; 20:303-16.

  41. 41.- Díaz Ramos RD. Las actividades del epidemiólogo en el comité de infecciones nosocomiales. [Cited 2006 August 20] Available from: URL: www.respyn.uanl.mx/especiales/ee-6-2003/08.pdf

  42. 42.- Díaz Ramos RD, Solórzano Santos F, Padilla Barrón G, Miranda Novales MG, González Robledo R, Trejo y Pérez JA. Infecciones nosocomiales. Experiencia en un hospital pediátrico de tercer nivel. Salud Pública Méx 1999; 41 (Suppl 1):S12-S17.

  43. 43.-Ávila Figueroa C, Casta Cruz M, Aranda Patrón E, León RA, Justiniano N, Pérez Ricárdez L, et al. Prevalencia de infecciones nosocomiales en niños: encuesta de 21 hospitales en México. Salud Pública Méx 1999; 41 (Suppl 1):S18-S25.

  44. 44.- Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms and associated risks. Clin Microbiol Rev 1997; 10:505-20.

  45. 45.- Enright MC. Genome of an epidemic community-acquired MRSA. Lancet 2006; 367:705-6.

  46. 46.- Naimi T S, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, et al. Comparision of community and health care-associated methicillin resistant Staphylococcus aureus infection. JAMA 2003; 290: 2976-84.

  47. 47.- Weber TJ. Community-Associated Methicillin Resistant Staphylococcus aureus. Clin Infect Dis 2005; 41:S269-72.

  48. 48.- Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus. Minnesota and North Dakota, 1997-1999. Morb Mortl Wkly Rep 1999; 48: 707-10.

  49. 49.- Charlebois ED, Bangsberg DR, Moss NJ, Moore MR, Moss AR, Chambers HF, Perdreau-Remington F. Population-based community prevalence of methicillin-resistant Sthapylococcus aureus in the urban poor of San Francisco. Clin Infect Dis 2002; 34:425-33.

  50. 50.- Shukla SK. Community-associated methicillin-resistant Sthapylococcus aureus and its emerging virulence. Clin Med Res 2005; 3:57-60.

  51. 51.- Centers for Disease Control and Prevention. Community-associated methicillin-resistant Staphylococcus aureus infection among healthy newborns-Chicago and Los Angeles County, 2004. Morb Mortl Wkly Rep 2006; 55:329-32.

  52. 52.- Broseta A, Chaves F, Rojo P, Otero JR. Emergencia de un clon de Staphylococcus aureus resistente a meticilina de origen comunitario en la población pediátrica del sur de Madrid. Enferm Infecc Microbiol Clin 2006; 24:31-5.

  53. 53.- Hisata K, Kuwahara-Arai K, Yamanoto M, Ito T, Nakatomi Y, Cui L, et al. Dissemination of methicillin-resistant staphylococci among healthy japanese children. J Clin Microbiol 2005; 43:3364-72.

  54. 54.- Vourli S, Perimeni D, Makri A, Polemis M, Voyiatzi A, Vatopoulos A. Communty acquired MRSA infections in a paediatric population in Greece. Euro Surveill 2005; 10:78-9.

  55. 55.- Wylie JL, Nowicki DL. Molecular epidemiology of community- and health care-associated methicillin-resistant Staphylococcus aureus in Manitoba, Canada. J Clin Microbiol 2005; 43:2830-36.

  56. 56.- Aramburu C, Harbarth S, Liassine N, Girard M, Gervaix A, Scherenzei J, et al. Communiyt-acquired methicillin-resistant Staphylococcus aureus in Switzerland: first survillance report. Euro Surveill 2006; 11:42-3.

  57. 57.- Ribeiro A, Dias C, Silva-Carvalho MC, Berquó L, Ferreira FA, Soares Santos RN, et al. Firts report of infection with community-acquired methicillin-resistant Staphylococcus aureus in South America. J Clin Microbiol 2005; 43:1985-8.

  58. 58.- Graham PL, Lin SX, Larson EL. A U.S. population-based survey of Staphylococcus aureus colonization. Ann Inter Med 2006; 144:318-25.

  59. 59.- Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2005; 41:S269-72.

  60. 60.- Vandenesch F, Naimi T, Enrigth MC, Lina G, Nimmo GR, Heffernan H, et al. Community-acquired methicilin-resistant. Staphylococcus aureus carrying Panton-Valentine leukocidin genes: world emergence. Emerg Infect Dis 2003; 9: 978-84.

  61. 61.- Lina G, Piémont Y, Godail-Gamont F, Bes M, Peter MO, Gauduchon V, et al. Involvement of Panton-Valentine Leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29:1128-32.

  62. 62.- Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, et al. Complete genome sequence of USA300, an epdemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 2006; 367:731-9.

  63. 63.- King MD, Humprey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA300 clone as the predominant cause of skin and soft tissue infections. Ann Inter Med 2006; 144:309-17.

  64. 64.- Fey PD, Saïd-Salim B, Rupp ME, Hinrichs SH, Boxrud DJ, Davis CC, et al. Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:196-203.

  65. 65.- Robinson DA, Kearns AM, Holmes A, Morrison D, Grundmann H, Edwards G, et al. Re-emergence of early pandemic Staphylococcus aureus as a communiyt-acquired meticillin-resistant clone. Lancet 2005; 365:1256-8.

  66. 66.- VandenBergh MFQ, Yzerman EPF, van Belkum A, Boelens HAM, Sijmons M, Verbrugh HA. Follow-up of Staphylococcus aureus nasal carriage after 8 years: redefining the persistent carrier state. J Clin Microb 1999; 37:3133-40.

  67. 67.- Peacock SJ, de Silva I, Lowy FD. What determines nasal carriage of Staphylococcus aureus? Trends Microbiology 2001; 9:605-10.

  68. 68.- Hu L, Umeda A, Kondo S, Amako K. Typing of Staphylococcus aureus colonising human nasal carriers by pulsed-field gel electrophoresis. J Med Microbiol 1995; 42:235-7.

  69. 69.- Kuehnert MJ, Kruzon-Moran D, Hill HA, McQuillan G, McAllister SK, Fosheim G, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis 2006; 193:172-9.

  70. 70.- Creech CB 2nd, Kernodle DS, Alsentzer A, Wilson C, Edwards KM. Increasing rates of nasal carriage of methicillin-resistant Staphylococcus aureus in healthy children. Pediatr Infect Dis J 2005; 24:617-21.

  71. 71.- Creech CB 2nd, Talbot TR, Schaffner W. Community-associated methicillin-resitant Staphylococcus aureus: the way to the wound is through the nose. J Infect Dis 2006; 193:169-71.

  72. 72.- Corbella X, Domínguez MA, Pujol M, Ayats J, Sendra M, Pallares R, et al. Staphylococcus aureus nasal carriage as a marker for subsequent staphylococcal infections in intensive care unit patients. Eur J Clin Microbiol Infect Dis 1997; 16:351-7.

  73. 73.- Tondo EC, Guimaraes MC, Henriques JA, Ayub MA. Assesing and analysing contamination of a dairy products processing plant by Staphylococcus aureus using antibiotic resistance and PFGE. Can J Microbiol 2000; 46:1108-14.

  74. 74.- Jones TF, Creech CB, Erwin P, Baird SG, Woron AM, Schaffner W. Family outbreaks of invasive community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2006; 42:76-8.




2020     |     www.medigraphic.com